Josh Bilenker

Josh Bilenker is the CEO and Co-Founder of Treeline Biosciences, a biotechnology company focused on developing innovative therapies for cancer. He has held this position since April 2021. Prior to founding Treeline, he served as the CEO of Loxo Oncology at Lilly, a subsidiary of Eli Lilly and Company, from December 2019 to January 2021. Loxo Oncology was acquired by Eli Lilly in February 2019, where Bilenker had previously been the founding CEO from July 2013 until its acquisition.134

Bilenker's career includes significant experience in both clinical and investment sectors. He worked as a life sciences venture capital investor at Aisling Capital LLC from 2006 to 2019, and prior to that, he served as a medical officer at the U.S. Food and Drug Administration in the Office of Oncology from 2004 to 2006.123

He holds an M.D. from The Johns Hopkins University School of Medicine and an A.B. in English from Princeton University. His medical training included a residency in internal medicine and medical oncology at the University of Pennsylvania, where he became board certified in these specialties.134

In addition to his role at Treeline, Bilenker is involved with several boards, including Gossamer Bio and Sana Biotechnology, further emphasizing his extensive experience in the biopharmaceutical field.35